ArticleJournal of clinical medicine2019
Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Radiological Loco-Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: An Updated Meta-analysis and Meta-regression.Cardiovascular and interventional radiology · 2024Pooled it
- Unresectable intrahepatic cholangiocarcinoma: TARE or TACE, which one to choose?Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Pooled it
- Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy.Current oncology (Toronto, Ont.) · 2022Pooled it
- Yttrium-90 Transarterial Radioembolization for Intrahepatic Cholangiocarcinoma: A Comprehensive Review.Journal of gastrointestinal cancer · 2026Review
- Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026Review
- The impact of alpha-lipoic acid treatment on various mediators of inflammatory and immune responses in a murine arthritis model.Inflammopharmacology · 2025Article
- Nanostructured lipid carriers in Rheumatoid Arthritis: treatment, advancements and applications.Inflammopharmacology · 2025Review
- Predictability of the radiological response to Yttrium-90 transarterial radioembolization by dynamic magnetic resonance imaging-based radiomics analysis in patients with intrahepatic cholangiocarcinomaDiagnostic and interventional radiology (Ankara, Turkey) · 2024Article
- Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.La Radiologia medica · 2024Article
- Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies.Cardiovascular and interventional radiology · 2024Article
- Any role for transarterial radioembolization in unresectable intrahepatic cholangiocarcinoma in the era of advanced systemic therapies?World journal of hepatology · 2023Review
- Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions.Seminars in interventional radiology · 2023Review
- Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization.Journal of gastrointestinal oncology · 2023Article
- Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?Cancers · 2023Review
- Review
- Review
- Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?Current oncology reports · 2022Review
- Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma-Role of Interventional Radiology.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate factors associated with survival following transarterial
methodsThis retrospective multicenter study analyzed the outcome of three tertiary care cancer centers in patients with advanced ICC following resin microsphere TARE. Patients were included either after failed previous anticancer therapy, including relapse after surgical resection, or for having a minimum of 25% of total liver volume affected by ICC. Patients were stratified and response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at 3 months. Kaplan-Meier analysis was performed to analyze survival followed by cox regression to determine independent prognostic factors for survival.
results46 patients were included (19 male, 27 female), median age 62.5 years (range 29-88 years). A total of 65% of patients had undergone previous therapy, while 63% had a tumor volume > 25% of the entire liver volume. Median survival was 9.5 months (95% CI: 6.1-12.9 months). Due to loss in follow-up, DISCUSSION: Survival after
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.